Comparing C4 Therapeutics (CCCC) & Its Competitors

C4 Therapeutics (NASDAQ:CCCC) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare C4 Therapeutics to similar businesses based on the strength of its valuation, risk, earnings, profitability, dividends, institutional ownership and analyst recommendations.

Insider & Institutional Ownership

78.8% of C4 Therapeutics shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 5.6% of C4 Therapeutics shares are owned by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for C4 Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
C4 Therapeutics	1	1	5	0	2.57
C4 Therapeutics Competitors	9893	15301	45654	1599	2.54

C4 Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 207.97%. As a group, “Biotechnology” companies have a potential upside of 126.24%. Given C4 Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe C4 Therapeutics is more favorable than its competitors.

Risk and Volatility

C4 Therapeutics has a beta of 3.16, suggesting that its share price is 216% more volatile than the S&P 500. Comparatively, C4 Therapeutics’ competitors have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.

Valuation & Earnings

This table compares C4 Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
C4 Therapeutics	$35.95 million	-$104.99 million	-3.83
C4 Therapeutics Competitors	$708.80 million	$10.27 million	-18.77

C4 Therapeutics’ competitors have higher revenue and earnings than C4 Therapeutics. C4 Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares C4 Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
C4 Therapeutics	-282.22%	-37.71%	-26.42%
C4 Therapeutics Competitors	-12,319.70%	-407.93%	-30.95%

Summary

C4 Therapeutics beats its competitors on 9 of the 13 factors compared.

About C4 Therapeutics

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts. Founded in 2015, it develops medicines designed to selectively remove disease-causing proteins, with a focus on cancer. The company uses its TORPEDO platform to design targeted protein degraders. These molecules are intended to bind a target protein and recruit the cell’s natural protein-disposal machinery, leading to the protein’s breakdown. C4 Therapeutics’ research and development programs include oral small-molecule candidates for oncology.